• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    11/12/24 1:45:06 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBM alert in real time by email
    SC 13G 1 sch13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )


    Psyence Biomedical Ltd.
    (Name of Issuer)
     
    Common Shares, no par value
    (Title of Class of Securities)
     
    74449F100
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event Which Requires Filing of the Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:


    ☒
    Rule 13d-1(b)

    ☐
    Rule 13d-1(c)

    ☐
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Page 1 of 5

    Cusip No. 74449F100
     
    Page 2 of 5 Pages
     
     
    1.
     
    NAME OF REPORTING PERSONS
     
    AdvisorShares Trust

     
    2.
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)  ☐    
    (b)  ☐    
     
     
    3.
     
    SEC USE ONLY
     
    4.
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
     NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
     
    5.

     SOLE VOTING POWER
     1,232,376
     
    6.

     SHARED VOTING POWER
     0
     
    7.

     SOLE DISPOSITIVE POWER
     1,232,376
     
    8.

     SHARED DISPOSITIVE POWER
     0
     
    9.

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     1,232,376
     
    10.

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     ☐
     
    11.

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     7.38%
     
    12.

     TYPE OF REPORTING PERSON (See Instructions)
     IV
             

    Page 2 of 5

    Cusip No. 74449F100
     
    Page 3 of 5 Pages

    Item 1(a).
    Name of Issuer:  Psyence Biomedical Ltd.

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    121 Richmond Street West
    Penthouse Suite 1300
    Toronto, Ontario M5H 2K1
    Canada

    Item 2(a).
    Name of Person Filing: AdvisorShares Trust

    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    4800 Montgomery Lane, Suite 150
    Bethesda, Maryland 20814

    Item 2(c).
    Citizenship: Delaware

    Item 2(d).
    Title of Class of Securities:  Common Shares, no par value

    Item 2(e).
    CUSIP Number: 74449F100

    Item 3.
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    [  ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C 78o);
           
     
    (b)
    [  ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C 78c);
           
     
    (c)
    [  ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C 78c);
           
     
    (d)
    [X]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
           
     
    (e)
    [ ]
    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
     
    (f)
    [  ]
    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
     
    (g)
    [  ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
     
    (h)
    [  ]
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
     
    (i)
    [  ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
     
    (j)
    [  ]
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
     
    (k)
    [   ]
    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
    _______________
     
    Page 3 of 5

    Cusip No. 74449F100
     
    Page 4 of 5 Pages

    Item 4.
    Ownership:

    Provide the following information regarding the aggregate number and percentage of class of securities of the issuer identified in Item 1.


    (a)
    Amount beneficially owned:  1,232,376


    (b)
    Percent of Class: 7.38%


    (c)
    Number of shares as to which such person has:


    (i)
    sole power to vote or to direct the vote: 1,232,376


    (ii)
    shared power to vote or to direct the vote: 0


    (iii)
    sole power to dispose or to direct the disposition of: 1,232,376


    (iv)
    shared power to dispose or to direct the disposition of: 0

    Item 5.
    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [  ].

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person:

    Not Applicable

    Item 7.
    Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not Applicable

    Item 8.
    Identification and Classification of Members of the Group:

    Not Applicable

    Item 9.
    Notice of Dissolution of Group:

    Not Applicable


    Page 4 of 5

    Cusip No. 74449F100
     
    Page 5 of 5 Pages

    Item 10. Certifications:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    November 12, 2024
     
    (Date)
       
     
    /s/ Stefanie Little
     
    (Signature)
       
     
    Stefanie Little – Chief Compliance Officer
     
    Name and Title

     

    Page 5 of 5
    Get the next $PBM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PBM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PBM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

    NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives. The visit follows recent U.S. policy developments supporting increased research collaboration, regulatory review pathways, and clinical investigation

    5/15/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company developing nature-derived psychedelic therapeutics, today announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting. The initiation of dosing represents the first active clinical evaluation of NPX-5 at scale and marks the Company's transition into systematic human data generation across its Australian clinical network. NPX-5 is a GMP-compliant, nature-derived psi

    4/23/26 7:00:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

    NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic therapies and manufacturing pharmaceutical-grade drug candidates, today provided an update on its strategic position in the global ibogaine market, as regulatory and clinical interest in the compound continues to expand. Recent signals from U.S. policymakers and global health authorities reflect increasing recognition of the need for structured, evidence-based evaluation of ibogaine, particularly in areas where existing treatment options remain limited. In anticipation of this shift, Psyence B

    4/20/26 7:42:20 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBM
    SEC Filings

    View All

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    4/23/26 4:15:15 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    4/20/26 8:25:16 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    4/17/26 4:59:56 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBM
    Financials

    Live finance-specific insights

    View All

    From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape

    DENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning's market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driven companies are pairing long-term vision with near-term execution. Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB): Spider Silk Moves From Legend to Industrial Reality Kraig Biocraft Laboratories set a distinctive tone with a detailed Christmas shareholder letter that framed 2025 as the company's inflection year, marking its transition from prolonged development into early commercialization of recombinant spider silk. The operational message was concrete, as Kraig Labs highlighted major adv

    12/19/25 9:48:44 AM ET
    $FOLD
    $PBM
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Psyence Biomedical Ltd.

    SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/13/24 9:16:01 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/9/24 1:36:43 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

    SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

    12/4/24 4:38:27 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBM
    Leadership Updates

    Live Leadership Updates

    View All

    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

    NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector. Through its investment in PsyLabs, Psyence BioMed has secured: A licensed, owned, and debt-free production operation.Source-level ibogaine supply.Natural psilocybin supply.GMP-compliant manufacturing capabilities.Intellectual property protection.Integrated analytical and chemistry laboratory infrastructure.A capital structur

    3/11/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

    NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement. Through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a naturally extracted, ethically sourced supply in Africa. Ibogaine HCl is the purified, stabilised, crystalline salt form of ibogaine used in clinical and therapeutic settings and represents the standard ph

    1/5/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care